Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 49

1.

Correction: The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML.

Kahl M, Brioli A, Bens M, Perner F, Kresinsky A, Schnetzke U, Hinze A, Sbirkov Y, Stengel S, Simonetti G, Martinelli G, Petrie K, Zelent A, Böhmer FD, Groth M, Ernst T, Heidel FH, Scholl S, Hochhaus A, Schenk T.

Leukemia. 2020 Jan 16. doi: 10.1038/s41375-020-0706-3. [Epub ahead of print]

PMID:
31949266
2.

Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN).

Brioli A, Manz K, Pfirrmann M, Hänel M, Schwarzer AC, Prange-Krex G, Fabisch C, Knop S, Illmer T, Krammer-Steiner B, Hochhaus A, von Lilienfeld-Toal M, Mügge LO.

J Cancer Res Clin Oncol. 2019 Dec 2. doi: 10.1007/s00432-019-03101-z. [Epub ahead of print]

PMID:
31788741
3.

The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML.

Kahl M, Brioli A, Bens M, Perner F, Kresinsky A, Schnetzke U, Hinze A, Sbirkov Y, Stengel S, Simonetti G, Martinelli G, Petrie K, Zelent A, Böhmer FD, Groth M, Ernst T, Heidel FH, Scholl S, Hochhaus A, Schenk T.

Leukemia. 2019 Nov;33(11):2628-2639. doi: 10.1038/s41375-019-0581-y. Epub 2019 Oct 1. Erratum in: Leukemia. 2020 Jan 16;:.

PMID:
31576004
4.

The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey.

Brioli A, Klaus M, Sayer H, Scholl S, Ernst T, Hilgendorf I, Scherag A, Yomade O, Schilling K, Hochhaus A, Mügge LO, von Lilienfeld-Toal M.

Ann Hematol. 2019 Mar;98(3):713-722. doi: 10.1007/s00277-019-03621-1. Epub 2019 Jan 24.

PMID:
30680505
5.

Safety issues and management of toxicities associated with new treatments for multiple myeloma.

Brioli A, Mügge LO, Hochhaus A, Von Lilienfeld-Toal M.

Expert Rev Hematol. 2017 Mar;10(3):193-205. doi: 10.1080/17474086.2017.1284584. Epub 2017 Jan 27. Review.

PMID:
28116920
6.

First line vs delayed transplantation in myeloma: Certainties and controversies.

Brioli A.

World J Transplant. 2016 Jun 24;6(2):321-30. doi: 10.5500/wjt.v6.i2.321. Review.

7.

Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens.

Tacchetti P, Cavo M, Rocchi S, Pezzi A, Pantani L, Brioli A, Testoni N, Terragna C, Zannetti BA, Mancuso K, Marzocchi G, Borsi E, Martello M, Rizzello I, Zamagni E.

Leuk Lymphoma. 2016 Sep;57(9):2058-64. doi: 10.3109/10428194.2015.1124994. Epub 2016 Jan 14.

PMID:
26763357
8.

Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma.

Pantani L, Brioli A, Tacchetti P, Zannetti BA, Mancuso K, Rocchi S, Martello M, Rizzello I, Terragna C, Zamagni E, Cavo M.

Expert Rev Hematol. 2016 Mar;9(3):315-23. doi: 10.1586/17474086.2016.1127754. Epub 2015 Dec 28. Review.

PMID:
26634945
9.

The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD).

Terragna C, Remondini D, Martello M, Zamagni E, Pantani L, Patriarca F, Pezzi A, Levi G, Offidani M, Proserpio I, De Sabbata G, Tacchetti P, Cangialosi C, Ciambelli F, Viganò CV, Dico FA, Santacroce B, Borsi E, Brioli A, Marzocchi G, Castellani G, Martinelli G, Palumbo A, Cavo M.

Oncotarget. 2016 Mar 1;7(9):9666-79. doi: 10.18632/oncotarget.5718.

10.

Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma.

Cavo M, Pantani L, Pezzi A, Petrucci MT, Patriarca F, Di Raimondo F, Marzocchi G, Galli M, Montefusco V, Zamagni E, Gamberi B, Tacchetti P, Brioli A, Palumbo A, Sonneveld P.

Leukemia. 2015 Dec;29(12):2429-31. doi: 10.1038/leu.2015.274. Epub 2015 Oct 7. No abstract available.

PMID:
26442610
11.

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.

Walker BA, Boyle EM, Wardell CP, Murison A, Begum DB, Dahir NM, Proszek PZ, Johnson DC, Kaiser MF, Melchor L, Aronson LI, Scales M, Pawlyn C, Mirabella F, Jones JR, Brioli A, Mikulasova A, Cairns DA, Gregory WM, Quartilho A, Drayson MT, Russell N, Cook G, Jackson GH, Leleu X, Davies FE, Morgan GJ.

J Clin Oncol. 2015 Nov 20;33(33):3911-20. doi: 10.1200/JCO.2014.59.1503. Epub 2015 Aug 17.

12.

PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma.

Zamagni E, Nanni C, Mancuso K, Tacchetti P, Pezzi A, Pantani L, Zannetti B, Rambaldi I, Brioli A, Rocchi S, Terragna C, Martello M, Marzocchi G, Borsi E, Rizzello I, Fanti S, Cavo M.

Clin Cancer Res. 2015 Oct 1;21(19):4384-90. doi: 10.1158/1078-0432.CCR-15-0396. Epub 2015 Jun 15.

13.

Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment.

Zannetti BA, Zamagni E, Santostefano M, De Sanctis LB, Tacchetti P, Mancini E, Pantani L, Brioli A, Rizzo R, Mancuso K, Rocchi S, Pezzi A, Borsi E, Terragna C, Marzocchi G, Santoro A, Cavo M.

Am J Hematol. 2015 Jul;90(7):647-52. doi: 10.1002/ajh.24035.

14.

Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation.

Brioli A, Perrone G, Patriarca F, Pezzi A, Nobile F, Ballerini F, Motta MR, Ronconi S, Tacchetti P, Catalano L, Zannetti BA, Rizzi S, Volpe S, Zamagni E, Liberati AM, Mancuso K, Boccadoro M, Davies FE, Morgan GJ, Palumbo A, Cavo M.

Bone Marrow Transplant. 2015 May;50(5):673-8. doi: 10.1038/bmt.2014.322. Epub 2015 Feb 2.

PMID:
25642764
15.

Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma.

Borsi E, Terragna C, Brioli A, Tacchetti P, Martello M, Cavo M.

Transl Res. 2015 Jun;165(6):641-50. doi: 10.1016/j.trsl.2014.12.001. Epub 2014 Dec 11. Review.

PMID:
25553605
16.

Biology and treatment of myeloma.

Brioli A, Melchor L, Walker BA, Davies FE, Morgan GJ.

Clin Lymphoma Myeloma Leuk. 2014 Sep;14 Suppl:S65-70. doi: 10.1016/j.clml.2014.06.011. Review.

PMID:
25486959
17.

Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations.

Pawlyn C, Melchor L, Murison A, Wardell CP, Brioli A, Boyle EM, Kaiser MF, Walker BA, Begum DB, Dahir NB, Proszek P, Gregory WM, Drayson MT, Jackson GH, Ross FM, Davies FE, Morgan GJ.

Blood. 2015 Jan 29;125(5):831-40. doi: 10.1182/blood-2014-07-584268. Epub 2014 Nov 26.

18.

HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment.

Borsi E, Perrone G, Terragna C, Martello M, Zamagni E, Tacchetti P, Pantani L, Brioli A, Dico AF, Zannetti BA, Rocchi S, Cavo M.

Exp Cell Res. 2014 Nov 1;328(2):444-55. doi: 10.1016/j.yexcr.2014.09.018. Epub 2014 Sep 26.

PMID:
25257607
19.

Peripheral neuropathy induced by subcutaneous bortezomib-based induction therapy for newly diagnosed multiple myeloma.

Brioli A, Zannetti BA, Zamagni E, Tacchetti P, Pantani L, Mancuso K, Pezzi A, Rocchi S, Cavo M.

Haematologica. 2014 Nov;99(11):e242-3. doi: 10.3324/haematol.2014.110221. Epub 2014 Aug 1. No abstract available.

20.

Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome.

Brioli A, Giles H, Pawlyn C, Campbell JP, Kaiser MF, Melchor L, Jackson GH, Gregory WM, Owen RG, Child JA, Davies FE, Cavo M, Drayson MT, Morgan GJ.

Blood. 2014 May 29;123(22):3414-9. doi: 10.1182/blood-2013-12-542662. Epub 2014 Apr 14.

PMID:
24733348

Supplemental Content

Loading ...
Support Center